Key Developments

On January 11, 2024, Harrow, a leading U.S. eyecare pharmaceutical company, announced that VEVYE (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug based on a “water‑free” semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money‑Back Guarantee program. VEVYE, given in a 10 microliter drop, is the first and only cyclosporine-based medicine approved to treat both signs and symptoms of dry eye disease (DED).
On January 9, 2024, Alcon, the world's leading eye care company dedicated to helping people see brilliantly, announced positive topline results from two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) assessing the efficacy and safety of AR-15512, a candidate treatment for dry eye disease (DED).
In June 2023, Novaliq GmbH, a biopharmaceutical company, stated that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of dry eye symptoms. VEVYE (development name CyclASol) is the first and only cyclosporine solution approved to treat the signs and symptoms of dry eye disease, with efficacy established after 4 weeks of treatment.
In May 2023, ENTOD Pharmaceuticals, a research-based pharmaceutical company, announced the launch of CYCLOTEARS eye drops for patients with Inflammatory Dry Eye Disease (DED) in India and for its various global markets. CYCLOTEARS eye drops would be the world's first dry eye treatment method to utilize the company's patented self-emulsifying drug delivery system (SEDDS) technology.